145 related articles for article (PubMed ID: 21737624)
41. Immunological protection induced by bacillus Calmette-Guérin treatment in a murine bladder tumor model.
Iwasaki A; Kawai K; Hayashi H; Ikeda N; Toida I; Ohtani M; Akaza H
Int J Urol; 2002 Apr; 9(4):219-24. PubMed ID: 12010317
[TBL] [Abstract][Full Text] [Related]
42. [Effect of BCG and BCG-CWS on experimental urinary bladder tumors in rats (author's transl)].
Kawakita J
Nihon Hinyokika Gakkai Zasshi; 1979 Nov; 70(11):1259-77. PubMed ID: 529653
[No Abstract] [Full Text] [Related]
43. Immunotherapy of cancer with cell wall skeleton of Myocabacterium bovis-Bacillus Calmette-Guérin: experimental and clinical results.
Yamamura Y; Azuma I; Taniyama T; Sugimura K; Hirao F; Tokuzen R; Okabe M; Nakahara W; Yasumoto K; Ohta M
Ann N Y Acad Sci; 1976; 277(00):209-27. PubMed ID: 826205
[TBL] [Abstract][Full Text] [Related]
44. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
[TBL] [Abstract][Full Text] [Related]
45. Successful regional immunotherapy with cell-wall skeletons of BCG and Nocardia rubra against autochthonous rat tumors.
Nagano N; Yasumoto K; Tanaka K; Ichinose Y; Yaita H; Nomoto K
Gan; 1982 Aug; 73(4):613-7. PubMed ID: 6759287
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant immunotherapy of lung cancer with BCG cell wall skeleton (BCG-CWS).
Yamamura Y; Sakatani M; Ogura T; Azuma I
Cancer; 1979 Apr; 43(4):1314-9. PubMed ID: 221088
[TBL] [Abstract][Full Text] [Related]
47. Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.
Gellings P; Galeas-Pena M; Morici LA
Clin Exp Med; 2023 Jun; 23(2):519-527. PubMed ID: 35076789
[TBL] [Abstract][Full Text] [Related]
48. Prophylaxis and therapy of an experimental bladder cancer with biological response modifiers.
Morales A; Pang AS
J Urol; 1986 Jan; 135(1):191-3. PubMed ID: 3941461
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy of murine transitional cell carcinoma.
Lamm DL; Reichert DF; Harris SC; Lucio RM
J Urol; 1982 Nov; 128(5):1104-8. PubMed ID: 6757465
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic effect of BCG cell-wall skeleton on the tumor induction by 7,12-dimethylbenz[a]anthracene in mice: strain difference.
Ikegami R; Takatsu K; Ono S; Hamaoka T; Fujiwara H; Kitagawa M; Azuma I; Yamamura Y
Gan; 1979 Feb; 70(1):101-7. PubMed ID: 109342
[TBL] [Abstract][Full Text] [Related]
51. Enhanced Intracellular Delivery of BCG Cell Wall Skeleton into Bladder Cancer Cells Using Liposomes Functionalized with Folic Acid and Pep-1 Peptide.
Yoon HY; Yang HM; Kim CH; Goo YT; Hwang GY; Chang IH; Whang YM; Choi YW
Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31817179
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy of human lung cancer with BCG cell-wall skeleton.
Yasumoto K; Manabe H; Ueno M; Ohta M; Ueda H
Gan; 1976 Dec; 67(6):787-95. PubMed ID: 798710
[TBL] [Abstract][Full Text] [Related]
53. Inhibitory effect of BCG cell-wall skeletons (BCG-CWS) emulsified in squalane on tumor growth and metastasis in mice.
Yoo YC; Hata K; Lee KB; Azuma I
Arch Pharm Res; 2002 Aug; 25(4):522-7. PubMed ID: 12214866
[TBL] [Abstract][Full Text] [Related]
54. Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.
Nishida S; Tsuboi A; Tanemura A; Ito T; Nakajima H; Shirakata T; Morimoto S; Fujiki F; Hosen N; Oji Y; Kumanogoh A; Kawase I; Oka Y; Azuma I; Morita S; Sugiyama H
Medicine (Baltimore); 2019 Aug; 98(33):e16771. PubMed ID: 31415377
[TBL] [Abstract][Full Text] [Related]
55. Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy.
Yuk JM; Shin DM; Song KS; Lim K; Kim KH; Lee SH; Kim JM; Lee JS; Paik TH; Kim JS; Jo EK
Autophagy; 2010 Jan; 6(1):46-60. PubMed ID: 19901560
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of Zhuling polyporus polysaccharide with BCG to inhibit bladder carcinoma.
Zhang GW; Qin GF; Han B; Li CX; Yang HG; Nie PH; Zeng X
Carbohydr Polym; 2015 Mar; 118():30-5. PubMed ID: 25542103
[TBL] [Abstract][Full Text] [Related]
57. Pharmaceutical characterization of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine used for the treatment of superficial bladder cancer.
Groves MJ
J Pharm Sci; 1993 Jun; 82(6):555-62. PubMed ID: 8331524
[TBL] [Abstract][Full Text] [Related]
58. Restorative effects of thymosin fraction 5 on reduction in responsiveness of rat thymocytes to allogenic lymphocytes during bladder tumor induction.
Asakawa M; Kinoshita Y; Kimura S; Hato F; Wada S; Nishijima T; Kishimoto T; Maekawa M
Cell Mol Biol; 1990; 36(3):265-74. PubMed ID: 2146022
[TBL] [Abstract][Full Text] [Related]
59. IMMUNOTHERAPY OF BLADDER CANCER. BCG VACCINE: PRINCIPLES OF ACTION, EFFICACY AND SAFETY.
Glybochko PV; Fisenko VP
Eksp Klin Farmakol; 2016; 79(10):34-43. PubMed ID: 30085482
[TBL] [Abstract][Full Text] [Related]
60. Effect of BCG cell-wall skeleton on metastasis of syngeneic tumor in rats, with special reference to lymphocyte trapping.
Ogura T; Namba M; Hirao F; Yamawaki M; Azuma I; Yamamura Y
Gan; 1978 Jun; 69(3):311-5. PubMed ID: 352783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
